The product is intended to be launched under the leading global antifungal brand Lamisil.

The agreement represents a further expansion of the strategic partnership initiated in November 2025, when Karo Healthcare obtained the rights to market, distribute and sell MOB-015 in 19 European markets with a combined population of approximately 500 million people. In April 2026, the collaboration was expanded to include Australia, New Zealand, South Korea and Taiwan, adding approximately 100 million potential consumers.

The license agreement applies to cross-border sales, providing Moberg Pharma full strategic flexibility to expand into the significantly larger general trade market in the future. Focusing on the smaller but rapidly growing cross-border sales channel enables a fast market entry, and a launch in China is expected to be carried out in parallel with launches in the first European countries under Karo’s brand.

This launch represents a first step in Moberg Pharma’s strategy for establishing a long-term presence in China, where entry into the general trade market would require the generation of additional data. Karo Healthcare is one of several potential partners also for general trade, and possesses the commercial infrastructure, distribution capabilities and local presence required to support it.

“This is further proof of the strong partnership we have built with Karo Healthcare. In less than a year, our collaboration has expanded from Europe to several markets in APAC, and now also China. Our ambition is to establish MOB-015 as a leading global treatment for nail fungus, and taking another step into the Chinese market is an important part of that journey,” says Anna Ljung, CEO of Moberg Pharma.

“China represents an exciting opportunity for MOB-015 and a natural next step in our collaboration with Moberg Pharma. We already have an established presence in the antifungal category through Lamisil® and look forward to introducing an innovative treatment for nail fungus to Chinese consumers,” says Michael Kaltenborn, Chief Strategy and Corporate Development Officer of Karo.